Octant Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
69
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$4.9M
- Investors
-
26
Octant General Information
Description
Developer of synthetic technology designed to improve health and treat disease. The company's platform uses synthetic biology, genome engineering, sequencing, and computational tools to simultaneously measure the activity of thousands of receptor pathways in human cells, enabling scientists to apply machine learning methods to engineer small molecules that interact with multiple receptors and unlock ways to treat complex diseases.
Contact Information
Website
www.octant.bioCorporate Office
- 6701 Hollis Street
- Emeryville, CA 94608
- United States
Corporate Office
- 6701 Hollis Street
- Emeryville, CA 94608
- United States
Octant Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Grant | 11-Jun-2025 | $4.9M | Completed | Clinical Trials - Phase 1 | ||
| 6. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 5. Later Stage VC (Series B) | 28-Apr-2022 | Completed | Clinical Trials - Phase 1 | |||
| 4. Early Stage VC (Series A) | 20-May-2020 | Completed | Clinical Trials - Phase 1 | |||
| 3. Accelerator/Incubator | 01-Jan-2019 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 01-Jan-2018 | $4.94M | $5.69M | Completed | Clinical Trials - Phase 1 | |
| 1. Accelerator/Incubator | $750K | $750K | Completed | Clinical Trials - Phase 1 |
Octant Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-1 | ||||||||
| Series A | 8,649,153 | $0.000010 | $0.21 | $3.47 | $3.47 | 1x | $3.47 | 24.34% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Octant Patents
Octant Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12697327-B2 | Pharmacological correctors of rhodopsin and uses thereof | Active | 28-Oct-2024 | ||
| US-20260115174-A1 | Pharmacological correctors of rhodopsin and uses thereof | Active | 28-Oct-2024 | ||
| US-20260345564-A1 | Pharmacological correctors of rhodopsin and uses thereof | Pending | 28-Oct-2024 | ||
| WO-2026096386-A1 | Pharmacological correctors of rhodopsin and uses thereof | Pending | 28-Oct-2024 | ||
| WO-2026039421-A1 | Nanoscale high-throughput chemistry screen | Pending | 13-Aug-2024 | C40B50/08 |
Octant Signals
Octant Investors (26)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Gates Foundation | Not-For-Profit Venture Capital | |||
| 10X Capital | Venture Capital | Minority | ||
| Bioverge | Venture Capital | Minority | ||
| Bristol-Myers Squibb | Corporation | Minority | ||
| Carbon Silicon Ventures | Venture Capital | Minority |
Octant FAQs
-
When was Octant founded?
Octant was founded in 2017.
-
Where is Octant headquartered?
Octant is headquartered in Emeryville, CA.
-
What is the size of Octant?
Octant has 69 total employees.
-
What industry is Octant in?
Octant’s primary industry is Drug Discovery.
-
Is Octant a private or public company?
Octant is a Private company.
-
What is Octant’s current revenue?
The current revenue for Octant is .
-
How much funding has Octant raised over time?
Octant has raised $116M.
-
Who are Octant’s investors?
Gates Foundation, 10X Capital, Bioverge, Bristol-Myers Squibb, and Carbon Silicon Ventures are 5 of 26 investors who have invested in Octant.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process